Michelly R. De Castro, BSN, MSN

Michelly De Castro practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Michelly De Castro's NPI, 1841687308, was assigned on April 22, 2015. Michelly De Castro holds Texas license 1072057.

Michelly De Castro's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Michelly De Castro's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service. Dmand AI also links Michelly De Castro to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Michelly De Castro practices. Vendor and product names are available with a free account.

Nurse practitioner is Michelly De Castro's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Michelly De Castro is licensed in Texas.

CMS counts 96 Medicare patients who saw Michelly De Castro in 2024. The largest group is 65 to 74, with 50 patients. 75% of them have high blood pressure, and 71% have high cholesterol. Their average risk score is 3.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Michelly De Castro's median patient age at 70, with 58% women.

In 2024, Michelly De Castro wrote 216 Medicare Part D claims for 66 patients. 99% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Michelly De Castro for performance year 2024, reported as part of a group. Michelly De Castro accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Michelly De Castro as offering telehealth.

CMS Open Payments shows 10 general payments to Michelly De Castro from 5 drug and device companies in 2025. Consulting fees make up the largest share, 77% of the total. Janssen Pharmaceuticals, Inc paid the most, $2,191.